SGLT2 Inhibitors in Elderly Patients: Clinical Perspectives from Metabolic and Cardiorenal Protection to Implementation
Journal of Clinical Medicine · 12.06.2026 · 15 (12) · 4578
DOI: 10.3390/jcm15124578 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 12.06.2026. Verfasst von Iris Parrini und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Unit, Koelliker Hospital, 10134 Torino, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The prevalence of diabetes and heart failure rises sharply with age, and their coexistence amplifies cardiovascular and renal risk. Elderly patients display unique clinical and biological profiles characterised by frailty, multimorbidity, and pharmacodynamic variability that challenge conventional treatment strategies. Sodium–glucose co-transporter-2 inhibitors (SGLT2i) have emerged as a cornerstone of cardio–renal–metabolic protection, with the most consistent cardiovascular benefit being the reduction in heart failure hospitalisation, whereas effects on cardiovascular death and major adverse cardiovascular events vary according to baseline cardiovascular risk, heart failure phenotype, diabetic status, and trial design. However, real-world use among the elderly remains limited due to concerns about tolerability, polypharmacy, and cost. This review analyses the pharmacological rationale and evidence base for SGLT2i therapy in older adults, highlighting mechanisms beyond glucose control, quantitative data from pivotal trials, and practical issues for geriatric implementation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiology Unit, Koelliker Hospital, 10134 Torino, Italy.
- Cardiology Unit, Giovanni Paolo II Hospital, 88046 Lamezia Terme, Italy.
- Cardiology Unit, Santa Maria Degli Ungheresi Hospital, Polistena, 89024 Reggio Calabria, Italy.
- Cardiology Department, Grande Ospedale Metropolitano of Reggio Calabria, 89124 Reggio Calabria, Italy.
- Cardiology Department, Garibaldi Nesima Hospital, 95122 Catania, Italy.
- Cardiothoracic Department, Maastricht University Hospital, 6229 Maastricht, The Netherlands.
ORCID-Profile: Iris Parrini, Fabiana Lucà, Sandro Gelsomino, Claudio Bilato, Giovanna Geraci, Fabrizio Oliva, Federico Nardi, Massimo Grimaldi
Zitieren
APA
Parrini, I., Ceravolo, R., Rao, C. M., Lucà, F., Gulizia, M. M., Gelsomino, S., Ingianni, N., Carullo, G., Quartuccio, S., Renne, S., Bilato, C., Geraci, G., Oliva, F., Nardi, F., & Grimaldi, M. (2026). SGLT2 Inhibitors in Elderly Patients: Clinical Perspectives from Metabolic and Cardiorenal Protection to Implementation. Journal of Clinical Medicine, 15(12), 4578. https://doi.org/10.3390/jcm15124578
Vancouver
Parrini I, Ceravolo R, Rao CM, Lucà F, Gulizia MM, Gelsomino S, et al. SGLT2 Inhibitors in Elderly Patients: Clinical Perspectives from Metabolic and Cardiorenal Protection to Implementation. Journal of Clinical Medicine. 2026;15(12):4578. doi:10.3390/jcm15124578
BibTeX
@article{Parrini2026,
author = {Parrini, Iris and Ceravolo, Roberto and Rao, Carmelo Massimiliano and Lucà, Fabiana and Gulizia, Michele Massimo and Gelsomino, Sandro and Ingianni, Nadia and Carullo, Giuseppe and Quartuccio, Sebastiano and Renne, Stefania and Bilato, Claudio and Geraci, Giovanna and Oliva, Fabrizio and Nardi, Federico and Grimaldi, Massimo},
title = {SGLT2 Inhibitors in Elderly Patients: Clinical Perspectives from Metabolic and Cardiorenal Protection to Implementation},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {12},
pages = {4578},
doi = {10.3390/jcm15124578}
}
EUVIMED